NA
COLL icon

Nordwand Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Nordwand Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-43
Closed -$1.03K – 123
2023
Q1 		$1.03K Buy
+43
New +$1.14K ﹤0.01% 123

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Nordwand Advisors's COLL Position: Q2 2023 in Review

Nordwand Advisors sold out of Collegium Pharmaceutical (COLL) in Q2 2023, closing a stake of 43 shares — an estimated $1.03K sold.

Nordwand Advisors first reported a position in COLL in Q1 2023 and held it in 1 quarter. The position peaked at $1.03K in Q1 2023. 178 funds tracked by Wall St. Rank hold COLL as of Q2 2023.

  • Nordwand Advisors reported no remaining Collegium Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Nordwand Advisors sold 43 Collegium Pharmaceutical shares in Q2 2023, an estimated $1.03K.
  • Nordwand Advisors first reported a position in Collegium Pharmaceutical in Q1 2023 and held it in 1 quarter.
  • Nordwand Advisors's Collegium Pharmaceutical position peaked at $1.03K in Q1 2023.
  • 178 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2023.

Based on Nordwand Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.